Will a Trastuzumab Biosimilar Work in Early HER2+ Breast Cancer?

The trastuzumab biosimilar ABP 980 showed noninferiority to trastuzumab in a large trial of patients with early HER2-positive breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

CONCLUSION: CD44+/CD24- phenotype was correlated with molecular subtypes of breast cancer. The highest expression of CD44+/CD24- phenotype was reported in patients with HER2+ disease, a molecular subtype associated with more aggressive behavior and worse prognosis.RESUMO INTRODU ÇÃO: De acordo com a teoria das células-tronco tumorais, os tumores são originários de uma pequena população de células-tronco que perdem o mecanismo de autorregulação e começam a se diferenciar e proliferar indefinidamente. O fenótipo CD44+/CD24- pode ser considera...
Source: Jornal Brasileiro de Patologia e Medicina Laboratorial - Category: Pathology Source Type: research
Conclusion We did not observe a relationship between MMP-9-1562 C/T polymorphism (rs 3918242) and the occurrence of breast cancer.Resumo Objetivo Estudos epidemiol ógicos vêm demonstrando evidências da influência de variações genéticas na patogênese do câncer de mama, e têm sugerido associação de polimorfismos comuma maior susceptibilidade à doença. A metalopeptidase dematriz 9 (MMP-9) é uma colagenase responsável pela degradação do colágeno tipo IV, omaior componente da membrana basal, e outros co...
Source: Revista Brasileira de Ginecologia e Obstetricia - Category: OBGYN Source Type: research
Dr. Charles Geyer discusses the phase III KATHERINE trial, which compared ado-trastuzumab emtansine vs trastuzumab in HER2-positive early breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Metastatic breast cancer treated with hormonal therapies can acquire mutations in HER2 and become treatment resistant, according to data published inNature Genetics.   MedicalXpress
Source: Society for Endocrinology - Category: Endocrinology Source Type: news
ConclusionsHigh Oncotype DX RS was associated with pCR after NCT in this national cohort of ER-positive, HER2-negative patients. Oncotype DX testing could help to identify patients most suited for NCT and should be considered for incorporation into the multidisciplinary decision-making process.
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
In patients with HER2-positive breast cancer treated with anthracyclines plus trastuzumab, can adding lisinopril or carvedilol reduce the risk of cardiotoxicity?
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
A comparison of chemotherapy regimens plus anti-HER2 therapy in the neoadjuvant setting tested whether the addition of anthracyclines is necessary for patients with HER2-positive breast cancer.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news
Condition:   Breast Cancer Interventions:   Drug: Letrozole;   Drug: Pyrotinib;   Drug: SHR6390 Sponsors:   Fudan University;   Jiangsu HengRui Medicine Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractIntroductionImprovement in overall survival (OS) by locoregional treatment (LRT) of the primary tumor in de novo metastatic breast cancer (MBC) patients remains controversial.ObjectiveThe aim of our study was to evaluate the impact of LRT on OS in a large retrospective cohort of de novo MBC patients, with regard to immunohistochemical characteristics and pattern of metastatic dissemination.MethodsWe conducted a multicentric retrospective study of patients diagnosed with de novo MBC selected from the French Epidemiological Strategy and Medical Economics MBC database (NCT03275311) between 2008 and 2014. Overall, 4276...
Source: Annals of Surgical Oncology - Category: Cancer & Oncology Source Type: research
HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases, Published online: 11 December 2018; doi:10.1038/s41388-018-0620-6HER2-positive breast-cancer cell lines are sensitive to KDM5 inhibition: definition of a gene-expression model for the selection of sensitive cases
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | HER2 | Herceptin